Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine
Dean Johnston, Jean‐Claude Bystryn
Vaccine (2005) Vol. 24, Iss. 11, pp. 1958-1965
Closed Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Effect of vaccine administration modality on immunogenicity and efficacy
Lu Zhang, Wei Wang, Shixia Wang
Expert Review of Vaccines (2015) Vol. 14, Iss. 11, pp. 1509-1523
Open Access | Times Cited: 212
Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant
Sylvia Adams, David O’Neill, Daisuke Nonaka, et al.
The Journal of Immunology (2008) Vol. 181, Iss. 1, pp. 776-784
Open Access | Times Cited: 245
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Evelien Smits, Peter Ponsaerts, Zwi Berneman, et al.
The Oncologist (2008) Vol. 13, Iss. 8, pp. 859-875
Open Access | Times Cited: 207
Immunization with a Toll-Like Receptor 7 and/or 8 Agonist Vaccine Adjuvant Increases Protective Immunity againstLeishmania majorin BALB/c Mice
Wen‐Wei Zhang, Greg Matlashewski
Infection and Immunity (2008) Vol. 76, Iss. 8, pp. 3777-3783
Open Access | Times Cited: 107
Selection of Adjuvants for Enhanced Vaccine Potency
Wei Wang, Manmohan Singh
World Journal of Vaccines (2011) Vol. 01, Iss. 02, pp. 33-78
Open Access | Times Cited: 85
Heat-killed Mycobacterium tuberculosis induces trained immunity in vitro and in vivo administered systemically or intranasally
Luna Minute, Marta Bergón-Gutiérrez, Pablo Mata-Martínez, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108869-108869
Open Access | Times Cited: 7
Therapeutic Dendritic Cell Vaccination of Patients With Metastatic Renal Cell Carcinoma
Annika Berntsen, Redas Trepiakas, Lynn Wenandy, et al.
Journal of Immunotherapy (2008) Vol. 31, Iss. 8, pp. 771-780
Closed Access | Times Cited: 96
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
Redas Trepiakas, Annika Berntsen, Sine Reker Hadrup, et al.
Cytotherapy (2010) Vol. 12, Iss. 6, pp. 721-734
Closed Access | Times Cited: 82
Resiquimod and other immune response modifiers as vaccine adjuvants
Mark A. Tomai, Richard L. Miller, Kenneth E. Lipson, et al.
Expert Review of Vaccines (2007) Vol. 6, Iss. 5, pp. 835-847
Closed Access | Times Cited: 81
Treatment Failure of a TLR-7 Agonist Occurs Due to Self-Regulation of Acute Inflammation and Can Be Overcome by IL-10 Blockade
Hailing Lu, Wolfgang Wagner, Ekram Gad, et al.
The Journal of Immunology (2010) Vol. 184, Iss. 9, pp. 5360-5367
Open Access | Times Cited: 80
Transcutaneous vaccines: Novel advances in technology and delivery for overcoming the barriers
Ni Li, Li‐Hua Peng, Xi Chen, et al.
Vaccine (2011) Vol. 29, Iss. 37, pp. 6179-6190
Closed Access | Times Cited: 73
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer
Daniela Fenoglio, Paolo Traverso, Alessia Parodi, et al.
Cancer Immunology Immunotherapy (2013) Vol. 62, Iss. 6, pp. 1041-1052
Open Access | Times Cited: 62
Anti-Cancer Immunotherapies Targeting Telomerase
Simone Negrini, Raffaele De Palma, Gilberto Filaci
Cancers (2020) Vol. 12, Iss. 8, pp. 2260-2260
Open Access | Times Cited: 50
Telomerase-based Cancer Therapeutics: A Review on their Clinical Trials
Nicola Relitti, A. Prasanth Saraswati, Stefano Federico, et al.
Current Topics in Medicinal Chemistry (2020) Vol. 20, Iss. 6, pp. 433-457
Closed Access | Times Cited: 49
Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response
Siva K. Gandhapudi, Martin Ward, John Peyton Bush, et al.
The Journal of Immunology (2019) Vol. 202, Iss. 12, pp. 3524-3536
Open Access | Times Cited: 42
Enhanced Immunogenicity ofPlasmodium falciparumPeptide Vaccines Using a Topical Adjuvant Containing a Potent Synthetic Toll-Like Receptor 7 Agonist, Imiquimod
Caroline Othoro, Dean Johnston, Rebecca Lee, et al.
Infection and Immunity (2008) Vol. 77, Iss. 2, pp. 739-748
Open Access | Times Cited: 57
TLR7 Triggering with Polyuridylic Acid Promotes Cross-Presentation in CD8α+ Conventional Dendritic Cells by Enhancing Antigen Preservation and MHC Class I Antigen Permanence on the Dendritic Cell Surface
María Inés Crespo, Estefanía R. Zacca, Nicolás Gonzalo Núñez, et al.
The Journal of Immunology (2013) Vol. 190, Iss. 3, pp. 948-960
Open Access | Times Cited: 41
Gel-like TPGS-Based Microemulsions for Imiquimod Dermal Delivery: Role of Mesostructure on the Uptake and Distribution into the Skin
Isabella Telò, Elena Del Favero, Laura Cantù, et al.
Molecular Pharmaceutics (2017) Vol. 14, Iss. 10, pp. 3281-3289
Closed Access | Times Cited: 35
Telomeres and Cancer
Hueng‐Chuen Fan, Fung-Wei Chang, Jeng-Dau Tsai, et al.
Life (2021) Vol. 11, Iss. 12, pp. 1405-1405
Open Access | Times Cited: 25
Topical resiquimod promotes priming of CTL to parenteral antigens
Brent A. Chang, Jennifer Cross, Hossain M. Najar, et al.
Vaccine (2009) Vol. 27, Iss. 42, pp. 5791-5799
Closed Access | Times Cited: 45
Conjugation of a TLR7 agonist and antigen enhances protection in the S. pneumoniae murine infection model
Simone Vecchi, Simone Bufali, Tetsuo Uno, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2014) Vol. 87, Iss. 2, pp. 310-317
Closed Access | Times Cited: 34
Rapid Vaccination Using an Acetalated Dextran Microparticulate Subunit Vaccine Confers Protection Against Triplicate Challenge by Bacillus Anthracis
Kevin L. Schully, Sadhana Sharma, Kevin J. Peine, et al.
Pharmaceutical Research (2013) Vol. 30, Iss. 5, pp. 1349-1361
Closed Access | Times Cited: 33
Nanoparticulate mediated transcutaneous immunization: Myth or reality
Monika Kaurav, Sunita Minz, Kantrol Kumar Sahu, et al.
Nanomedicine Nanotechnology Biology and Medicine (2016) Vol. 12, Iss. 4, pp. 1063-1081
Closed Access | Times Cited: 31
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines
Dean Johnston, Bushra Zaidi, Jean‐Claude Bystryn
Cancer Immunology Immunotherapy (2006) Vol. 56, Iss. 8, pp. 1133-1141
Open Access | Times Cited: 43
An update on the use of laser technology in skin vaccination
Xinyuan Chen, Ji Wang, Dilip Shah, et al.
Expert Review of Vaccines (2013) Vol. 12, Iss. 11, pp. 1313-1323
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top